Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

SRR1313145

· D

c4c187b7-f270-5f0f-8472-0e6b2f7b376e

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
cancer_type_detailed
subtype
D
subtype
D

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • G2M_CHECKPOINT+0.410
  • E2F_TARGETS+0.370
  • MITOTIC_SPINDLE+0.290
  • WNT_BETA_CATENIN_SIGNALING+0.180
  • SPERMATOGENESIS+0.120
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.100
  • DNA_REPAIR+0.020
  • KRAS_SIGNALING_DN+0.020
  • MYOGENESIS+0.020
  • NOTCH_SIGNALING+0.020

Top 10 suppressed

  • ESTROGEN_RESPONSE_EARLY-0.500
  • INTERFERON_ALPHA_RESPONSE-0.460
  • FATTY_ACID_METABOLISM-0.390
  • ESTROGEN_RESPONSE_LATE-0.380
  • PANCREAS_BETA_CELLS-0.380
  • ADIPOGENESIS-0.360
  • MYC_TARGETS_V2-0.360
  • BILE_ACID_METABOLISM-0.330
  • PI3K_AKT_MTOR_SIGNALING-0.320
  • XENOBIOTIC_METABOLISM-0.310

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

7 twins match this tumor's tissue · 3 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-58-8388-01A-11R-2326-07
lung-landscapes@6
cohortSQ10.834
2a9e8922f-fd6c-412d-85f5-40f5ea9b5455
colon-landscapes@1
0.819
3MNG790
mng-umap@100
0.817
4BS_9FHSNVS0
brain-umap@2
ATRT0.815
5TCGA-AC-A2QH-01B-04R-A22O-07
breast-umap@18
D0.803
6SRR10899974
melanoma-umap@29
0.796
7BS_S1M423AB
brain-umap@2
Embryonal tumors0.790
820120197.TNBC
breast-umap@18
D0.790
9BS_4E1G7E3G
brain-umap@2
ATRT0.786
10TCGA-BA-4078-01A-01R-1436-07
head-neck@1
0.784

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 11 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
G2M_CHECKPOINT0.410Inavolisib— uncovered
E2F_TARGETS0.370Inavolisib— uncovered
MITOTIC_SPINDLE0.290Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.180Inavolisib— uncovered
SPERMATOGENESIS0.120Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.100Inavolisib— uncovered
DNA_REPAIR0.020Idelalisib— uncovered
KRAS_SIGNALING_DN0.020Remibrutinib— uncovered
MYOGENESIS0.020Inavolisib— uncovered
NOTCH_SIGNALING0.020Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.020Inavolisib— uncovered